The Technology Co.,Ltd. (KOSDAQ:043090)
South Korea
· Delayed Price · Currency is KRW 1,140.00
-39.00 (-3.31%)
At close: Apr 7, 2025
The Technology Revenue
In the year 2025, The Technology had annual revenue of 12.58B KRW with 21.82% growth. The Technology had revenue of 6.38B in the quarter ending December 31, 2025, with 153.44% growth.
Revenue
12.58B
Revenue Growth
+21.82%
P/S Ratio
0.38
Revenue / Employee
449.16M
Employees
28
Market Cap
4.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.58B | 2.25B | 21.82% |
| Dec 31, 2024 | 10.32B | -4.58B | -30.75% |
| Dec 31, 2023 | 14.91B | 11.01B | 282.57% |
| Dec 31, 2022 | 3.90B | -4.95B | -55.96% |
| Dec 31, 2021 | 8.85B | 3.64B | 69.94% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
| Dec 31, 2013 | Pro | Pro | Pro |
| Dec 31, 2012 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Femtobiomed | 389.96M |
| Genotech | 7.28B |
| Angiolab | 702.62M |
| OLIPASS | 5.25B |
| Apures | 517.33M |
| Moogene Medi | 12.95M |
| NGeneBio | 21.24B |
| Epibiotech | 449.62M |